Want to see HK:1875 full AI Analyst Report?
1875 Stock Chart & Stats
HK$2.50
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$2.50
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$1.70 - HK$5.87
Previous CloseN/A
Volume400.00
Average Volume (3M)240.51K
Market Cap
HK$2.77B
Enterprise ValueHK$2.11B
Total Cash (Recent Filing)HK$328.47M
Total Debt (Recent Filing)HK$383.72M
Price to Earnings (P/E)―
Beta0.54
Next Earnings
Aug 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding772,787,900
10 Day Avg. Volume141,880
30 Day Avg. Volume240,506
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)2.60
Price to Sales (P/S)2.18
P/FCF Ratio-60.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$4.40Price Target Upside76.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.18
Revenue Forecast (FY)HK$566.06M
Bulls Say, Bears Say
Bulls Say
Diversified Revenue Streams (product Sales + CDMO)Having both oncology product sales and CDMO/CMO service revenue creates durable revenue diversification. CDMO contracts tend to be multi-period and service-driven, providing steadier cash inflows and reducing reliance on single-product commercialization outcomes over a 2–6 month horizon.
In-house GMP Manufacturing And R&D CapabilitiesVertical integration with in-house GMP manufacturing and clinical development supports product supply continuity and underpins CDMO credibility. These capabilities serve as structural competitive advantages, enabling recurring third-party contracts and protecting margins versus outsourced peers over medium-term planning cycles.
Manageable Leverage And Balance Sheet StabilityA moderate debt profile gives the company financial flexibility to fund R&D and manufacturing operations despite cyclical earnings. This balance sheet headroom is a durable buffer that supports continued operations and strategic investments without immediate refinancing stress over the coming months.
Bears Say
Sharp 2025 Revenue Decline And Return To LossesA ~32% revenue drop and swing back to losses represent structural execution or demand issues that reduce internal funding for pipeline programs and commercial expansion. This weakens self-funding capacity and heightens refinancing and operational risk over multiple quarters.
Persistently Negative Free Cash FlowSustained negative free cash flow forces reliance on external financing or asset sales to fund operations and capex. Over the medium term this constrains discretionary R&D investment, delays commercialization timing, and increases dilution or leverage risk if cash generation does not recover.
Profitability Volatility And Margin CompressionVolatile profitability with compressed gross margins indicates weakening pricing power, adverse mix, or rising costs. Margin instability increases the probability of repeated earnings setbacks and limits ability to build retained earnings, raising the structural difficulty of attaining sustained profitability.
TOT BIOPHARM International Co. Ltd. News
1875 FAQ
What was TOT BIOPHARM International Co. Ltd.’s price range in the past 12 months?
TOT BIOPHARM International Co. Ltd. lowest stock price was HK$1.70 and its highest was HK$5.87 in the past 12 months.
What is TOT BIOPHARM International Co. Ltd.’s market cap?
TOT BIOPHARM International Co. Ltd.’s market cap is HK$2.77B.
When is TOT BIOPHARM International Co. Ltd.’s upcoming earnings report date?
TOT BIOPHARM International Co. Ltd.’s upcoming earnings report date is Aug 18, 2026 which is in 36 days.
How were TOT BIOPHARM International Co. Ltd.’s earnings last quarter?
TOT BIOPHARM International Co. Ltd. released its earnings results on Mar 18, 2026. The company reported -HK$0.148 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.148.
Is TOT BIOPHARM International Co. Ltd. overvalued?
According to Wall Street analysts TOT BIOPHARM International Co. Ltd.’s price is currently Undervalued.
Does TOT BIOPHARM International Co. Ltd. pay dividends?
TOT BIOPHARM International Co. Ltd. does not currently pay dividends.
What is TOT BIOPHARM International Co. Ltd.’s EPS estimate?
TOT BIOPHARM International Co. Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TOT BIOPHARM International Co. Ltd. have?
TOT BIOPHARM International Co. Ltd. has 772,787,900 shares outstanding.
What happened to TOT BIOPHARM International Co. Ltd.’s price movement after its last earnings report?
TOT BIOPHARM International Co. Ltd. reported an EPS of -HK$0.148 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.695%.
Which hedge fund is a major shareholder of TOT BIOPHARM International Co. Ltd.?
Currently, no hedge funds are holding shares in HK:1875
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TOT BIOPHARM International Co. Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$4.40 (76.00% Upside)
HK$4.40 (76.00% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.06%
12-Months-Change
Fundamentals
Return on Equity
-14.78%
Trailing 12-Months
Asset Growth
-12.65%
Trailing 12-Months
Company Description
TOT BIOPHARM International Co. Ltd.
BioDlink International Co., Ltd. operates as a clinical-stage biopharmaceutical firm, dedicating its resources to the development and future commercialization of novel oncology drugs and therapeutic solutions. Its pipeline features several key product candidates, including TAB008, TOZ309, TAA013, TAE020, TAB 014, and TAC020. The company was founded on December 4, 2009, and its primary base of operations is situated in Suzhou, China.
1875 Stock 12 Month Forecast
Average Price Target
HK$4.40
▲(76.00% Upside)
Technical Analysis
Alphamab Oncology
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Lepu Biopharma Co. Ltd. Class H
―
CARsgen Therapeutics Holdings Ltd.
―
Shanghai Henlius Biotech, Inc. Class H
―